European Federation of Neurological Societies/Peripheral Nerve Society Guideline* onmanagement of paraproteinemic demyelinating neuropathies. Report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society

Robert D. Hadden, Eduardo Nobile-Orazio, Claudia Sommer, Angelika Hahn, Isabel Illa, Enrica Morra, John D. Pollard, Richard A C Hughes, Pierre Bouche, David Cornblath, Eileen Evers, Carol L. Koski, Jean Marc Léger, Peter Van Den Bergh, Pieter A. Van Doorn, Ivo N. Van Schaik

Research output: Contribution to journalArticle

Abstract

Background: Paraprotein-associated neuropathies have heterogeneous clinical, neurophysiological, neuropathological, and hematological features. Objectives: The aim of this guideline was to prepare evidence-based and consensus guidelines on the clinical management of patients with both a demyelinating neuropathy and a paraprotein [paraproteinemic demyelinating neuropathy (PDN)]. Methods: Disease experts and a representative of patients considered references retrieved from MEDLINE and the Cochrane Library and prepared statements that were agreed in an iterative fashion. Recommendations: In the absence of adequate data, evidence-based recommendations were not possible, but the Task Force agreed on the following good practice points: (1) patients with PDN should be investigated for a malignant plasma cell dyscrasia; (2) the paraprotein is more likely to be causing the neuropathy if the paraprotein is immunoglobulin M (IgM), antibodies are present in serum or on biopsy, or the clinical phenotype is chronic distal sensory neuropathy; (3) patients with IgM PDN usually have predominantly distal and sensory impairment, with prolonged distal motor latencies, and often anti-myelin-associated glycoprotein antibodies; (4) IgM PDN sometimes responds to immunotherapies. Their potential benefit should be balanced against their possible side effects and the usually slow disease progression; (5) IgG and IgA PDN may be indistinguishable from chronic inflammatory demyelinating polyradiculoneuropathy clinically, electrophysiologically, and in response to treatment; and (6) for POEMS syndrome, local irradiation or resection of an isolated plasmacytoma, or melphalan with or without corticosteroids, should be considered, with hemato-oncology advice.

Original languageEnglish (US)
Pages (from-to)9-19
Number of pages11
JournalJournal of the Peripheral Nervous System
Volume11
Issue number1
DOIs
StatePublished - Mar 2006
Externally publishedYes

Fingerprint

Paraproteins
Advisory Committees
Joints
Guidelines
Immunoglobulin M
POEMS Syndrome
Myelin-Associated Glycoprotein
Chronic Inflammatory Demyelinating Polyradiculoneuropathy
Patient Advocacy
Paraproteinemias
Melphalan
Plasmacytoma
Antibodies
MEDLINE
Immunotherapy
Immunoglobulin A
Libraries
Disease Progression
Adrenal Cortex Hormones
Immunoglobulin G

Keywords

  • Definition
  • Diagnosis
  • Guidelines
  • Paraproteinemic demyelinating neuropathy
  • Treatment

ASJC Scopus subject areas

  • Clinical Neurology
  • Neuroscience(all)

Cite this

European Federation of Neurological Societies/Peripheral Nerve Society Guideline* onmanagement of paraproteinemic demyelinating neuropathies. Report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society. / Hadden, Robert D.; Nobile-Orazio, Eduardo; Sommer, Claudia; Hahn, Angelika; Illa, Isabel; Morra, Enrica; Pollard, John D.; Hughes, Richard A C; Bouche, Pierre; Cornblath, David; Evers, Eileen; Koski, Carol L.; Léger, Jean Marc; Van Den Bergh, Peter; Van Doorn, Pieter A.; Van Schaik, Ivo N.

In: Journal of the Peripheral Nervous System, Vol. 11, No. 1, 03.2006, p. 9-19.

Research output: Contribution to journalArticle

Hadden, Robert D. ; Nobile-Orazio, Eduardo ; Sommer, Claudia ; Hahn, Angelika ; Illa, Isabel ; Morra, Enrica ; Pollard, John D. ; Hughes, Richard A C ; Bouche, Pierre ; Cornblath, David ; Evers, Eileen ; Koski, Carol L. ; Léger, Jean Marc ; Van Den Bergh, Peter ; Van Doorn, Pieter A. ; Van Schaik, Ivo N. / European Federation of Neurological Societies/Peripheral Nerve Society Guideline* onmanagement of paraproteinemic demyelinating neuropathies. Report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society. In: Journal of the Peripheral Nervous System. 2006 ; Vol. 11, No. 1. pp. 9-19.
@article{71157c0b4e1d463da775afd31a05240e,
title = "European Federation of Neurological Societies/Peripheral Nerve Society Guideline* onmanagement of paraproteinemic demyelinating neuropathies. Report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society",
abstract = "Background: Paraprotein-associated neuropathies have heterogeneous clinical, neurophysiological, neuropathological, and hematological features. Objectives: The aim of this guideline was to prepare evidence-based and consensus guidelines on the clinical management of patients with both a demyelinating neuropathy and a paraprotein [paraproteinemic demyelinating neuropathy (PDN)]. Methods: Disease experts and a representative of patients considered references retrieved from MEDLINE and the Cochrane Library and prepared statements that were agreed in an iterative fashion. Recommendations: In the absence of adequate data, evidence-based recommendations were not possible, but the Task Force agreed on the following good practice points: (1) patients with PDN should be investigated for a malignant plasma cell dyscrasia; (2) the paraprotein is more likely to be causing the neuropathy if the paraprotein is immunoglobulin M (IgM), antibodies are present in serum or on biopsy, or the clinical phenotype is chronic distal sensory neuropathy; (3) patients with IgM PDN usually have predominantly distal and sensory impairment, with prolonged distal motor latencies, and often anti-myelin-associated glycoprotein antibodies; (4) IgM PDN sometimes responds to immunotherapies. Their potential benefit should be balanced against their possible side effects and the usually slow disease progression; (5) IgG and IgA PDN may be indistinguishable from chronic inflammatory demyelinating polyradiculoneuropathy clinically, electrophysiologically, and in response to treatment; and (6) for POEMS syndrome, local irradiation or resection of an isolated plasmacytoma, or melphalan with or without corticosteroids, should be considered, with hemato-oncology advice.",
keywords = "Definition, Diagnosis, Guidelines, Paraproteinemic demyelinating neuropathy, Treatment",
author = "Hadden, {Robert D.} and Eduardo Nobile-Orazio and Claudia Sommer and Angelika Hahn and Isabel Illa and Enrica Morra and Pollard, {John D.} and Hughes, {Richard A C} and Pierre Bouche and David Cornblath and Eileen Evers and Koski, {Carol L.} and L{\'e}ger, {Jean Marc} and {Van Den Bergh}, Peter and {Van Doorn}, {Pieter A.} and {Van Schaik}, {Ivo N.}",
year = "2006",
month = "3",
doi = "10.1111/j.1085-9489.2006.00059.x",
language = "English (US)",
volume = "11",
pages = "9--19",
journal = "Journal of the Peripheral Nervous System",
issn = "1085-9489",
publisher = "Wiley-Blackwell",
number = "1",

}

TY - JOUR

T1 - European Federation of Neurological Societies/Peripheral Nerve Society Guideline* onmanagement of paraproteinemic demyelinating neuropathies. Report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society

AU - Hadden, Robert D.

AU - Nobile-Orazio, Eduardo

AU - Sommer, Claudia

AU - Hahn, Angelika

AU - Illa, Isabel

AU - Morra, Enrica

AU - Pollard, John D.

AU - Hughes, Richard A C

AU - Bouche, Pierre

AU - Cornblath, David

AU - Evers, Eileen

AU - Koski, Carol L.

AU - Léger, Jean Marc

AU - Van Den Bergh, Peter

AU - Van Doorn, Pieter A.

AU - Van Schaik, Ivo N.

PY - 2006/3

Y1 - 2006/3

N2 - Background: Paraprotein-associated neuropathies have heterogeneous clinical, neurophysiological, neuropathological, and hematological features. Objectives: The aim of this guideline was to prepare evidence-based and consensus guidelines on the clinical management of patients with both a demyelinating neuropathy and a paraprotein [paraproteinemic demyelinating neuropathy (PDN)]. Methods: Disease experts and a representative of patients considered references retrieved from MEDLINE and the Cochrane Library and prepared statements that were agreed in an iterative fashion. Recommendations: In the absence of adequate data, evidence-based recommendations were not possible, but the Task Force agreed on the following good practice points: (1) patients with PDN should be investigated for a malignant plasma cell dyscrasia; (2) the paraprotein is more likely to be causing the neuropathy if the paraprotein is immunoglobulin M (IgM), antibodies are present in serum or on biopsy, or the clinical phenotype is chronic distal sensory neuropathy; (3) patients with IgM PDN usually have predominantly distal and sensory impairment, with prolonged distal motor latencies, and often anti-myelin-associated glycoprotein antibodies; (4) IgM PDN sometimes responds to immunotherapies. Their potential benefit should be balanced against their possible side effects and the usually slow disease progression; (5) IgG and IgA PDN may be indistinguishable from chronic inflammatory demyelinating polyradiculoneuropathy clinically, electrophysiologically, and in response to treatment; and (6) for POEMS syndrome, local irradiation or resection of an isolated plasmacytoma, or melphalan with or without corticosteroids, should be considered, with hemato-oncology advice.

AB - Background: Paraprotein-associated neuropathies have heterogeneous clinical, neurophysiological, neuropathological, and hematological features. Objectives: The aim of this guideline was to prepare evidence-based and consensus guidelines on the clinical management of patients with both a demyelinating neuropathy and a paraprotein [paraproteinemic demyelinating neuropathy (PDN)]. Methods: Disease experts and a representative of patients considered references retrieved from MEDLINE and the Cochrane Library and prepared statements that were agreed in an iterative fashion. Recommendations: In the absence of adequate data, evidence-based recommendations were not possible, but the Task Force agreed on the following good practice points: (1) patients with PDN should be investigated for a malignant plasma cell dyscrasia; (2) the paraprotein is more likely to be causing the neuropathy if the paraprotein is immunoglobulin M (IgM), antibodies are present in serum or on biopsy, or the clinical phenotype is chronic distal sensory neuropathy; (3) patients with IgM PDN usually have predominantly distal and sensory impairment, with prolonged distal motor latencies, and often anti-myelin-associated glycoprotein antibodies; (4) IgM PDN sometimes responds to immunotherapies. Their potential benefit should be balanced against their possible side effects and the usually slow disease progression; (5) IgG and IgA PDN may be indistinguishable from chronic inflammatory demyelinating polyradiculoneuropathy clinically, electrophysiologically, and in response to treatment; and (6) for POEMS syndrome, local irradiation or resection of an isolated plasmacytoma, or melphalan with or without corticosteroids, should be considered, with hemato-oncology advice.

KW - Definition

KW - Diagnosis

KW - Guidelines

KW - Paraproteinemic demyelinating neuropathy

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=33644787369&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33644787369&partnerID=8YFLogxK

U2 - 10.1111/j.1085-9489.2006.00059.x

DO - 10.1111/j.1085-9489.2006.00059.x

M3 - Article

VL - 11

SP - 9

EP - 19

JO - Journal of the Peripheral Nervous System

JF - Journal of the Peripheral Nervous System

SN - 1085-9489

IS - 1

ER -